The effect is smaller than the 20% prostate cancer mortality reduction observed in the ERSPC study as the current PSA uptake pattern is less intensive than ERSPC and the lower biopsy compliance observed in Sweden (see Table B in S1 Appendix). Here, KLK3 is linked to prostate cancer.